Clinical trial · Observational
Glioblastoma Platelet Activation Study
NCT02887417CI-TRIAL-00028862GPAScompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Glioblastoma face an increased risk of venous or arterial thromboembolism. Furthermore, the most frequent immune cells in glioblastoma are tumor associated macrophages, which find theirself in an anti-inflammatory (M2) phenotype. Increased conjugates between circulating platelets and monocytes reflect an pro-inflammatory status.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Circulating Platelet-monocyte Conjugates | — | UNRESOLVED | — |
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- patients
- description
- glioblastoma patients
- label
- controls
- description
- healthy controls
Primary outcomes (4)
- measure
- Mean P-selectine expression in all platelets
- timeFrame
- 01/ 2016 - 10/ 2016
- measure
- Mean CD63 expression in all platelets
- timeFrame
- 01/ 2016 - 10/ 2016
- measure
- Mean CD40 Expression in all platelets
- timeFrame
- 01/ 2016 - 10/ 2016
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * MR-morphological suspicion for glioblastoma * informed consent Exclusion Criteria: * no informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.